The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
 
Yara Abdou
Honoraria - Clinical Care Options; MJH Associates; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Exact Sciences
Research Funding - Carisma Therapeutics (Inst)
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Elizabeth Claire Dees
Consulting or Advisory Role - Novartis (I); Sanofi
Research Funding - H3 Biomedicine; Merck; Meryx Pharmaceuticals; Pfizer
 
Joanne E. Mortimer
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Puma Biotechnology
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
(OPTIONAL) Uncompensated Relationships - Pfizer; SEAGEN
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Richard T. Maziarz
Honoraria - Novartis; Omeros
Consulting or Advisory Role - Artiva; Incyte; Intellia Therapeutics; Novartis
Patents, Royalties, Other Intellectual Property - Athersys
 
Jennifer M. Specht
Honoraria - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline; Sensei Biotherapeutics
Consulting or Advisory Role - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline; Sensei Biotherapeutics
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Celcuity (Inst); Genentech (Inst); Merck (Inst); Minerva Biotechnologies (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - GE Healthcare; GlaxoSmithKline; Nektar
 
Yuan Yuan
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech; Gilead Sciences; Merck; Pfizer
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
Naoto T. Ueno
Stock and Other Ownership Interests - Pear Bio
Honoraria - Amgen; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Henry Stewart Talks; Kyowa Hakko Kirin; Kyowa Kirin International; Novartis; Pfizer; Pfizer; Puma Biotechnology; Rakuten Medical; Sumitomo Dainippon Pharma Oncology; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Carna Biosciences; Daiichi Sankyo; Eisai; Immunomedics; Kechow Pharma; OncoCyte; Phoenix Molecular Designs; Preferred Medicine; Takeda
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; CytoDyn; Daiichi Sankyo; Duality Biologics; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex
 
Mathew Angelos
No Relationships to Disclose
 
Saar Gill
Stock and Other Ownership Interests - Carisma Therapeutics; Interius Biotherapeutics
Consulting or Advisory Role - Asher Biotherapeutics
Research Funding - Carisma Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents for chimeric antigen receptor T cells for acute myeloid leukemia
 
Amy Ronczka
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Thomas Condamine
Employment - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Daniel Cushing
Employment - Carisma Therapeutics
Leadership - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Debora Barton
Employment - Advanced Accelerator Applications; Carisma Therapeutics; Iovance Biotherapeutics; TScan Therapeutics
Leadership - Arovella Therapeutics
Stock and Other Ownership Interests - Advanced Accelerator Applications; Arovella Therapeutics; Carisma Therapeutics; Iovance Biotherapeutics
 
Michael Klichinsky
Employment - Carisma Therapeutics
Leadership - Carisma Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Ramona F. Swaby
Employment - Carisma Therapeutics; Merck; Prelude Therapeutics
Stock and Other Ownership Interests - Carisma Therapeutics; Merck
Travel, Accommodations, Expenses - Merck
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)